PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1307918-0	1992	Effect of a cholecystokinin antagonist, proglumide, on cholecystokinin-8-induced gallbladder contraction in conscious dogs.	Proglumide	40-50	cholecystokinin	Canis lupus familiaris	12-27	
1307918-0	1992	Effect of a cholecystokinin antagonist, proglumide, on cholecystokinin-8-induced gallbladder contraction in conscious dogs.	Proglumide	40-50	cholecystokinin	Canis lupus familiaris	55-70	
1307918-1	1992	The objective of this study was to characterize the effect of proglumide, a cholecystokinin (CCK) antagonist, on gallbladder contraction stimulated by CCK in conscious dogs.	Proglumide	62-72	cholecystokinin	Canis lupus familiaris	76-91	
1307918-1	1992	The objective of this study was to characterize the effect of proglumide, a cholecystokinin (CCK) antagonist, on gallbladder contraction stimulated by CCK in conscious dogs.	Proglumide	62-72	cholecystokinin	Canis lupus familiaris	93-96	
1307918-1	1992	The objective of this study was to characterize the effect of proglumide, a cholecystokinin (CCK) antagonist, on gallbladder contraction stimulated by CCK in conscious dogs.	Proglumide	62-72	cholecystokinin	Canis lupus familiaris	151-154	
1307918-3	1992	The results of this study show that proglumide, given as an intravenous bolus (2.5, 5, 10, 20, and 40 mg/kg) or as a continuous intravenous infusion (150 or 300 mg/kg/h, 10 min), can block the stimulatory action of CCK in a dose-related manner.	Proglumide	36-46	cholecystokinin	Canis lupus familiaris	215-218	
1307918-4	1992	Bolus administration of proglumide resulted in a transient inhibition, whereas continuous infusion of proglumide resulted in a prolonged antagonism of CCK-stimulated gallbladder contraction.	Proglumide	102-112	cholecystokinin	Canis lupus familiaris	151-154	
1307918-5	1992	Review of the data leads to the conclusion that the antagonistic action of intravenously administered proglumide on CCK-stimulated gallbladder contraction may be characterized as rapid and reversible.	Proglumide	102-112	cholecystokinin	Canis lupus familiaris	116-119	
2858160-2	1985	The recent description of the drug proglumide as a specific, competitive cholecystokinin (CCK)/gastrin receptor antagonist has permitted reevaluation of the role of CCK in this process.	Proglumide	35-45	cholecystokinin	Canis lupus familiaris	73-88	
1886888-8	1991	The stimulatory effect as well as potentiating effect of CCK on pancreatic bicarbonate secretion was blocked by infusion of proglumide.	Proglumide	124-134	cholecystokinin	Canis lupus familiaris	57-60	
3446223-0	1987	Biological effects of a proglumide derivative as cholecystokinin antagonist in conscious dogs.	Proglumide	24-34	cholecystokinin	Canis lupus familiaris	49-64	
1886888-4	1991	However, the increase in bicarbonate as well as protein secretion was blocked by proglumide, a CCK antagonist, given intravenously.	Proglumide	81-91	cholecystokinin	Canis lupus familiaris	95-98	
2927258-5	1989	Proglumide, 10 mg/Kg, did not produce colonic contractions itself, but antagonized CCK-OP-induced responses.	Proglumide	0-10	cholecystokinin	Canis lupus familiaris	83-86	
2858160-2	1985	The recent description of the drug proglumide as a specific, competitive cholecystokinin (CCK)/gastrin receptor antagonist has permitted reevaluation of the role of CCK in this process.	Proglumide	35-45	cholecystokinin	Canis lupus familiaris	90-93	
2858160-2	1985	The recent description of the drug proglumide as a specific, competitive cholecystokinin (CCK)/gastrin receptor antagonist has permitted reevaluation of the role of CCK in this process.	Proglumide	35-45	cholecystokinin	Canis lupus familiaris	165-168	
2858160-3	1985	In chronic pancreatic fistula dogs, dose-response studies were performed to determine the effect of proglumide on the pancreatic responses to octapeptide of CCK (CCK-OP), intravenous bethanechol, intraduodenal amino acids, and intraduodenal fat.	Proglumide	100-110	cholecystokinin	Canis lupus familiaris	157-160	
2858160-4	1985	Pancreatic volume, protein, and bicarbonate outputs to all doses of CCK-OP were inhibited significantly (P less than 0.05) in a competitive manner, consistent with the proposed mode of action of proglumide.	Proglumide	195-205	cholecystokinin	Canis lupus familiaris	68-74	
2858160-7	1985	If indeed proglumide is a specific CCK receptor antagonist, these results support the hypothesis that CCK is the major mediator of the intestinal phase of exocrine pancreatic secretion.	Proglumide	10-20	cholecystokinin	Canis lupus familiaris	35-38	
2858160-7	1985	If indeed proglumide is a specific CCK receptor antagonist, these results support the hypothesis that CCK is the major mediator of the intestinal phase of exocrine pancreatic secretion.	Proglumide	10-20	cholecystokinin	Canis lupus familiaris	102-105	
6729149-6	1984	Proglumide might be useful in defining the physiological role of CCK.	Proglumide	0-10	cholecystokinin	Canis lupus familiaris	65-68